Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
PR Newswire - Mon Mar 31, 12:00PM CDT
"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation"
Resverlogix Update
CNW Group - Mon Mar 17, 1:16PM CDT
"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets"
Resverlogix Board Update
CNW Group - Tue Feb 11, 4:00PM CST
TSX Exchange Symbol: RVX
Resverlogix Conference Call & Webcast Announcement
CNW Group - Thu Feb 06, 3:30PM CST
TSX Exchange Symbol: RVX
Resverlogix Announces Combined RVX-208 Findings from SUSTAIN & ASSURE Phase 2b Trials
PR Newswire Europe - Thu Jan 16, 4:54AM CST
CALGARY, Alberta, January 15, 2014 /PRNewswire/ --
Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
CNW Group - Thu Jan 02, 1:53PM CST
TSX Exchange Symbol: RVX
Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
PR Newswire - Mon Dec 23, 7:00AM CST
TSX Exchange Symbol: RVX
Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability
PR Newswire - Mon Nov 04, 7:00AM CST
"RVX-208 lowers Inflammation and MACE Events while Regressing Atheroma in High Risk CVD Patients"
Stockboard Custom Reports on Resverlogix Corp. and Medicago Inc.
ACCESSWIRE - Tue Sep 03, 12:04PM CDT
Custom stock reports and email news alert service for Resverlogix Corp. (TSX:RVX) and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF) are now available on Stockboard.com
Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
PR Newswire Europe - Tue Sep 03, 7:30AM CDT
CALGARY, Alberta, September 3, 2013 /PRNewswire/ --